country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99041B

Copy Link Print Information

Panitumumab (powder)

(Synonyms: ABX-EGF (powder))

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer.

For research use only. We do not sell to patients.

CAS No.: 339177-26-3
Molecular Weight:144.32 kDa

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (262 KB)

Panitumumab (powder) Chemical Structure

CAS No.: 339177-26-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (2)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isotype

Human IgG2 kappa

Recommend Isotype Controls

Human IgG2 kappa, Isotype Control

Species Reactivity

Human

All EGFR Isoforms :

In Vitro

Panitumumab (2 nM-2 μM, 3 h) (powder) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells^[3].
Panitumumab (0-200 μg/mL, 48 h) (powder)inhibits the proliferation of DLD-1 cells^[4].
Panitumumab (80 μg/mL, 24 h) (powder) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:

2, 20, 200, 2000 nM
Incubation Time:

3 h
Result:

Inhibited ligand-induced autophosphorylation of EGFR.

In Vivo

Panitumumab (25-500 μg per mouse, i.p., twice a week) (powder) inhibits tumor growth in the xenograft models of NCI-H1975 and NCI-H1650 in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NCI-H1975 and NCI-H1650 xenografts^[3]
Dosage:

25, 100, or 500 μg/mouse
Administration:

Intraperitoneal injection (i.p.), twice a week
Result:

Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

1956 [NCBI]

Accession

P00533

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Application

ELISA, FACS, Functional assay

Chemical Information

CAS No. 339177-26-3
Molecular Weight 144.32 kDa
SMILES

[Panitumumab (powder)]
Synonyms

ABX-EGF (powder)
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All WBIF

Sort by:

Journal Impact Factor

Sci Rep

Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. [Abstract]

2022 Jul 7;12(1):11561. PMID: 35798841

Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]

HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.

Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]

Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.
Electrophoresis

A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]

2026 Mar 24. PMID: 41873887

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (262 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . . [Content Brief]

[2]. Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9. [Content Brief]

[3]. Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51. [Content Brief]

[4]. Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546. [Content Brief]

[5]. Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Panitumumab (powder)

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
Chemical Information
Publications (2)
Purity & Documentation
References

1/16

Product Image
1/16

Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]

Customer Validation
HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.
1/16

Panitumumab (powder) purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561. [Abstract]

Customer Validation
Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.
1/16

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Panitumumab (powder)

Publications Citing Use of MedChemExpress (MCE) Panitumumab (powder)

All EGFR Isoforms

Biological Activity

Chemical Information

Publications (2)

Purity & Documentation

References

Calculators

Help & FAQs

Panitumumab (powder) Related Classifications

HY-P99041B Related Classifications